Resveratrol has various attractive bioactivities, such as prevention of cancer, neurodegenerative disorders, and obesity-related diseases. Therefore, identifying its direct binding proteins is expected to discover druggable targets. Sirtuin 1 and phosphodiesterases have so far been found as the direct molecular targets of resveratrol. We herein identified 11 novel resveratrol-binding proteins, including the DEAD (Asp-Glu-Ala-Asp) box helicase 5 (DDX5, also known as p68), using resveratrol-immobilized beads. Treatment with resveratrol induced degradation of DDX5 in prostate cancer cells. Depletion of DDX5 caused apoptosis by inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling. Moreover, knockdown of DDX5 attenuated the inhibitory activities of resveratrol against mTORC1 signaling and cancer cell growth. These data show that resveratrol directly targets DDX5 and induces cancer cell death by inhibiting the mTORC1 pathway.

In advanced bladder cancer, cisplatin-based chemotherapy has been the standard treatment for many years, but there are many problems in terms of side-effects. Recently, a number of clinical trials using molecular-targeted agents have been conducted, and new therapies are expected that could replace conventional cytotoxic chemotherapy. We herein report that concurrent treatment with fibroblast growth factor receptor (FGFR) inhibitor BGJ398 and the novel histone deacetylase (HDAC) inhibitor OBP-801/YM753/spiruchostatin A synergistically inhibited cell growth and markedly induced apoptosis in high-grade bladder cancer cells. This combination activated caspase-3, -8 and -9, and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the combined treatment. The combination upregulated the expression of Bim, one of the pro-apoptotic molecules. In the present study, Bim siRNA efficiently reduced apoptosis induced by the co-treatment of BGJ398 and OBP-801. Therefore, the apoptosis induced by the combination was shown to be at least partially dependent on Bim. Taken together, these results suggest that the combination of BGJ398 and OBP-801 is a novel high potential therapeutic strategy for muscle-invasive bladder cancer.

The prognosis of muscle-invasive bladder cancer with metastasis is poor. There have been no therapeutic improvements for many years, and an innovative therapy for muscle-invasive bladder cancer has been awaited to replace the conventional cytotoxic chemotherapy. Here, we show a candidate method for the treatment of bladder cancer. The combined treatment with a novel histone deacetylase (HDAC) inhibitor, OBP-801, and celecoxib synergistically inhibited cell growth and markedly induced apoptosis through the caspase-dependent pathway in high-grade bladder cancer cells. Furthermore, the combined treatment induced expression of death receptor 5 (DR5). We identified that knockdown of DR5 by small interfering RNA (siRNA) significantly suppressed apoptosis by the combined treatment. Therefore, we conjectured that the apoptosis induced by OBP-801 and celecoxib is at least partially dependent on DR5. However, it was interesting that the combined treatment drastically suppressed expression of DR5 ligand, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). These data suggest that there is no involvement of TRAIL in the induction of apoptosis by the combination, regardless of the dependence of DR5. Moreover, xenograft studies using human bladder cancer cells showed that the combined therapy suppressed tumor growth by upregulating expressions of DR5 and Bim. The inhibition of tumor growth was significantly more potent than that of each agent alone, without significant weight loss. This combination therapy provided a greater benefit than monotherapy in vitro and in vivo. These data show that the combination therapy with OBP-801 and celecoxib is a potential novel therapeutic strategy for patients with muscle-invasive bladder cancer. Mol Cancer Ther; 15(9); 2066-75. Ó2016 AACR.

No abstract

<p>T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. A. Quantitative real-time RT-PCR of DR5 mRNA. The internal control was β2MG. Values show fold change in DR5 expression compared with control (DMSO treatment). Data represent the means of triplicates with SD. B. Cells were stained with PE-labeled mouse anti-human DR5 monoclonal antibody and PE-labeled IgG isotype control. Data were analyzed by flow cytometry. Overlaid histogram is shown in the upper panels. DMSO treatment (gray histogram), OBP-801 treatment (dashed line), celecoxib treatment (dotted line), and combined treatment (solid line). In the lower panels, values show fold change of the geometric mean values in the expression of DR5/IgG. Columns, means of triplicate data; bars, SD; **, P<0.01.</p>

<p>T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. Quantitative real-time RT-PCR of FLIP (A) and survivin (B) mRNA were performed. The internal control was β2MG. Values show fold change in the target gene expression compared with control (DMSO treatment). Data represent the means of triplicates with SD.</p>

<p>A. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 72 h. Quantitative real-time RT-PCR of TRAIL mRNA was performed. The internal control was β2MG. Values show fold change in TRAIL mRNA expression compared with control (DMSO treatment). Data represent the means of triplicates with SD. B. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib with or without DR5/Fc chimera for 72 h. Sub-G1 populations were analyzed by flow cytometry. C. UM-UC-11 cells were treated with the indicated concentrations of TRAIL or PBS, followed by the treatment with OBP-801 and/or celecoxib at the indicated concentrations. After incubation for 96 h, cell counts were assessed by CCK-8 assay. Columns, means of triplicate data; bars, SD; **, P<0.01. D. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib with or without TRAIL for 72 h. Sub-G1 populations were analyzed by flow cytometry. Columns, means of triplicate data; bars, SD; **, P<0.01.</p>

The remitting seronegative symmetrical synovitis with pitting edema syndrome primarily occurs in elderly individuals to represent symptoms of edema, pain, and joint swelling. It could be misdiagnosed in elderly maintenance hemodialysis patients, as hemodialysis patients often present with pain and joint swelling induced by hypervolemia, inflammation, amyloidosis, and/or chronic kidney disease. Here, we describe a maintenance hemodialysis patient with remitting seronegative symmetrical synovitis with pitting edema syndrome. Case presentation: A 71-year-old man on maintenance hemodialysis who complained of continuous pain and swelling of joints was diagnosed with remitting seronegative symmetrical synovitis with pitting edema syndrome on his clinical findings that revealed tenosynovitis at the joint without joint erosions and no elevation of anti-cyclic citrullinated peptide antibody and rheumatoid factor. After administration of prednisolone, systemic edema, and pain improved in 2 days. Conclusion: Remitting seronegative symmetrical synovitis with pitting edema syndrome should be considered as a differential diagnosis in hemodialysis patients with edema and/or arthralgia.